Doxorubicin liposome injection vials contain glass particulate matter
Doxorubicin Hydrochloride Liposome Injection, 50 mg/25 mL single-dose vials, is being recalled because of particulate matter identified as glass. 675 vials are affected.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA Class I recall, which the rubric floors at Severe; no injury is reported in the source, so it does not escalate to Critical.
Plain-English summary
Doxorubicin Hydrochloride Liposome Injection, 50 mg/25 mL (2 mg/mL), 25 mL sterile single-dose vials, prescription only, manufactured for Northstar Rx LLC of Memphis, Tennessee by Sun Pharmaceutical Industries, is being recalled. The action covers 675 vials.
The stated reason is the presence of particulate matter identified as glass. The FDA classified the action as Class I, its most serious classification.
The affected lot is HAG2581B, expiring 05/31/2027. Distribution was USA nationwide. The vials are supplied to healthcare providers rather than sold directly to consumers.
Facilities should identify affected stock using the lot number above, quarantine it, and follow the instructions issued by the manufacturer.
The recalled product
- Product
- DOXORUBICIN HYDROCHLORIDE (DOXORUBICIN HYDROCHLORIDE)
- Brand
- DOXORUBICIN HYDROCHLORIDE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Injectable oncology drug
- Affected units
- 675
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot HAG2581B
- expires: 05/31/2027
UPCs (1)
- 0372603200010
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DOXORUBICIN HYDROCHLORIDE
- ModerateFresenius Kabi Recalls Doxorubicin Hydrochloride Injection Due to Cross-Contamination
FDA (Drugs) · 2020-12-02
- SevereSun Pharmaceutical Recalls Doxorubicin Hydrochloride Injection Due to Sterility Concerns
FDA (Drugs) · 2018-01-31
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- ModerateXyvona levorphanol tablets recalled after FDA denied the proprietary name
FDA (Drugs) · 2026-06-10
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26